In-vivo CAR-T therapy - Thesian Bio
Latest Information Update: 04 Nov 2025
At a glance
- Originator Thesian Bio
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Haematological malignancies; Solid tumours
Most Recent Events
- 30 Oct 2025 Early research in Autoimmune disorders in France (Parenteral)
- 30 Oct 2025 Early research in Haematological malignancies in France (Parenteral), before October 2025 (Argobio Studio website, October 2025), before October 2025 (Argobio Studio website, October 2025)
- 30 Oct 2025 Early research in Solid tumours in France (Parenteral), before October 2025 (Argobio Studio website, October 2025)